Agilent Technologies, Inc. (NYSE:A).
On July 11 Morgan Stanley made no change to the company rating of “Overweight” but raised the price expectation to $75.00 from $55.00. Equity analyst Leerink Swann issued its first research report on the stock giving it an initial rating of “Outperform”.
August 18 investment analysts at Baird made no change to the stock rating of “Outperform” but raised the price target from $46.00 to $52.00. On August 18 BTIG Research maintained a stock rating of “Outperform” but moved down the price target from $55.00 to $51.00.
August 18 investment analysts at Cowen & Company left the stock rating at “” and raised the price target to $51.00 from $49.00.
The company is so far trading up by 1.56% since yesterday’s close of $59.8. The company also announced a dividend to be paid on Wednesday the 26th of July 2017. The dividend payment will be $0.133 per share for the quarter which is $0.53 annualized. The dividend yield will be $0.88. The ex-dividend date is set for Thursday the 29th of June 2017.
Shares of the company are trading at $60.73 marginally over the 50 day moving average of $58.94 and just above the 200 day moving average of $52.92. The 50 day moving average was up $1.79 or +3.04% and the 200 day average went up $7.81 or +14.76%.
Agilent Technologies, Inc., launched on May 4, 1999, provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. The Company has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. The life sciences and applied markets business segment brings together the Business’s analytical laboratory instrumentation and informatics. The Business’s diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. The Business’s Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio..
The company’s P/E ratio is 34.14 and the market cap of the company is 19.51B. As of the last earnings report the EPS was $1.78 and is projected to be $2.23 for the current year with 321,337,000 shares now outstanding. Next quarter’s EPS is forecasted at $0.60 and the next full year EPS is projected to be $2.53.